Literature DB >> 19578352

Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease?

Noel W Clarke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19578352     DOI： 10.1038/nrurol.2009.105

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer.

Authors:  Laurence Koltz; Noel Clarke
Journal:  Eur Urol       Date:  2008-02-20       Impact factor: 20.096

2.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

3.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

4.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 6.  Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Urol       Date:  2009-02-26       Impact factor: 7.450

Review 7.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Clin Oncol       Date:  2009-02-24       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.